---
canonical_name: Selegiline
alternate_names: L-Deprenyl, Deprenyl, Selegiline Hydrochloride, Eldepryl, Zelapar, Emsam, Jumex
canonical_topic: Selegiline for Health & Longevity
short_topic_lc: selegiline
creation_date: 2026-0629-0951
creator_ai_fullname: Opus 4.8
---

# Selegiline for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 06/29/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** L-Deprenyl, Deprenyl, Selegiline Hydrochloride, Eldepryl, Zelapar, Emsam, Jumex


## Motivation

<!-- This motivation section was written only after the rest of the document was completed, so it reflects the full scope of the topic. -->

Selegiline (also known as L-Deprenyl) is a prescription medicine first developed in the 1960s and approved decades ago to treat Parkinson's disease and, in a skin-patch form, depression. It works mainly by blocking an enzyme in the brain that breaks down dopamine, a chemical messenger tied to movement, motivation, and mood. Because that enzyme becomes more active with age, the drug has drawn interest from people who hope that preserving dopamine could slow some features of brain aging.

What sets selegiline apart in longevity circles is animal research, started by the Hungarian scientist who discovered it, suggesting low doses can lengthen the average lifespan of rats and other animals. Pooled analyses point to a fairly consistent lifespan benefit, making it one of the more frequently replicated candidate longevity compounds in animals, though some famous individual results have looked weaker on closer inspection. Whether any of this carries over to healthy humans remains untested.

This review examines what the evidence shows about selegiline as a healthy-aging compound: how it works, the strength of the animal lifespan data, the gap between animal and human findings, its established risks and interactions, and the practical and dosing questions that surround its off-label use.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level, accessible overviews that discuss selegiline and its longevity rationale directly.

<!-- Real-time web searches were performed for "selegiline" and "deprenyl" combined with longevity terms across general web search and the prioritized expert platforms (Rhonda Patrick / foundmyfitness.com, Peter Attia / peterattiamd.com, Andrew Huberman / hubermanlab.com, Chris Kresser / chriskresser.com, Life Extension / lifeextension.com). No dedicated, substantial selegiline content was found on the Patrick, Attia, Huberman, or Kresser platforms; relevant overviews were found on Life Extension and from independent life-extension authors. -->

* [Can Deprenyl (Selegiline) Extend Human Lifespan?](https://www.benbest.com/lifeext/deprenyl.html) - Ben Best

A detailed, sourced layperson's review tracing Knoll's original rat lifespan experiments, the conflicting Parkinson's mortality data, and the argument for why longevity dosing differs from disease dosing. It is one of the most thorough non-academic syntheses of the longevity case.

* [How Dopamine Protects the Aging Brain](https://www.lifeextension.com/magazine/2022/9/dopamine-protects-against-brain-aging) - Michael Downey

An accessible feature on age-related dopamine decline and the role of MAO-B (the enzyme selegiline blocks), framing why preserving dopamine is a longevity target and noting that increasing dopamine has extended lifespan in animals.

* [Deprenyl: 50 Years of Life Enhancement and Life Extension](https://www.antiaging-systems.com/articles/deprenyl-50-years-of-life-enhancement-and-life-extension/) - Leslie J. Farer

A long-form historical overview of deprenyl's discovery and the half-century of animal and human research on its proposed neuroprotective and life-extending effects, useful for context on how the compound entered longevity practice.

*Note: Only three high-quality, directly relevant overviews from distinct organizations could be found. No dedicated, substantial selegiline content exists on the Rhonda Patrick, Peter Attia, Andrew Huberman, or Chris Kresser platforms, so none of the prioritized experts contributed; the list was not padded with marginally relevant or duplicate-source content (including a second International Antiaging Systems article) to reach five.*


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "Selegiline"; a dedicated article exists at the page below. -->

* [Selegiline](https://grokipedia.com/page/Selegiline) - Grokipedia

A comprehensive AI-generated reference entry covering selegiline's pharmacology, MAO-B selectivity, clinical uses in Parkinson's disease and depression, and the animal longevity literature, useful as a single consolidated starting point.


## Examine

<!-- examine.com was searched directly using the browser tool for "selegiline"; the site returned "Sorry, there are no search results for selegiline." -->

No Examine article exists for selegiline. Examine.com focuses on dietary supplements and does not typically cover prescription medications such as selegiline.


## ConsumerLab

<!-- consumerlab.com was searched directly for "selegiline"; the search returned only tangential supplement results (e.g., L-Tyrosine) and no dedicated selegiline article. -->

No ConsumerLab article exists for selegiline. ConsumerLab tests dietary supplements for quality and does not typically cover prescription medications such as selegiline.


## Systematic Reviews

This section lists systematic reviews and meta-analyses most relevant to selegiline's longevity and clinical evidence base, prioritized by relevance, recency, and study size.

* [L-deprenyl extends lifespan across mammalian species: A meta-analysis of 22 longevity experiments](https://pubmed.ncbi.nlm.nih.gov/40816452/) - Bene, 2025

This random-effects meta-analysis of 22 rodent lifespan experiments found L-Deprenyl significantly increased average lifespan with a moderate effect size, with larger effects at higher doses and older starting age; it also re-analyzed a dog survival study and found no significant effect after adjustment. It is the single most directly relevant source for the longevity question.

* [Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/37113570/) - Wang et al., 2023

Pooling 27 randomized controlled trials (RCTs, studies that randomly assign participants to treatment or placebo) and 11 observational studies, it found selegiline improved motor scores with longer treatment but raised the risk of adverse events, mainly neuropsychiatric. It anchors the human safety and efficacy picture.

* [Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations](https://pubmed.ncbi.nlm.nih.gov/37087864/) - Rossano et al., 2023

This review of 42 studies found selegiline outperformed placebo for depression, including atypical depression, while increasing dry mouth, insomnia, and skin-patch reactions; confidence in most findings was low. It is the most complete summary of selegiline's mood effects.

* [Effects and safety of monoamine oxidase-B inhibitors for early Parkinson's disease: A network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/39278214/) - Wang & Wang, 2024

A network meta-analysis of 30 trials ranking selegiline, rasagiline, safinamide, and zonisamide; all beat placebo on motor scores, with rasagiline ranked most effective. It places selegiline in context against newer MAO-B inhibitors.

* [Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis](https://pubmed.ncbi.nlm.nih.gov/9748034/) - Olanow et al., 1998

A pooled analysis of five long-term trials that found no increase in mortality with selegiline, contradicting an earlier alarming report; it directly addresses the historical safety controversy that shaped the compound's reputation.


## Mechanism of Action

Selegiline's defining action is irreversible, selective inhibition of monoamine oxidase type B (MAO-B), an enzyme that breaks down dopamine and certain other brain chemicals. By disabling MAO-B, selegiline slows the breakdown of dopamine, raising its availability in dopamine-using brain circuits. Because MAO-B activity rises substantially with age, the drug's rationale as a longevity agent is that it partly offsets this age-related increase.

Beyond simply preserving dopamine, selegiline is proposed to be neuroprotective through several routes. Inhibiting MAO-B reduces production of hydrogen peroxide (a reactive oxidant) generated when dopamine is broken down, lowering oxidative stress. Animal work also reports that selegiline increases activity of protective antioxidant enzymes — superoxide dismutase (SOD, which neutralizes free radicals) and catalase — in specific brain regions, and that some of its metabolites and the compound itself may reduce programmed cell death (apoptosis) of neurons. Joseph Knoll, its discoverer, additionally proposed a separate "catecholaminergic activity enhancer" effect, independent of MAO-B inhibition, by which low doses increase impulse-triggered release of dopamine and noradrenaline.

A competing interpretation tempers these mechanisms. Critics note that the antioxidant and anti-apoptotic findings come largely from animal and cell models at doses or conditions that may not translate to humans, and that the lifespan benefit in animals may partly reflect general central-nervous-system stimulation or appetite and activity effects rather than a specific longevity pathway. Whether MAO-B inhibition itself is the operative mechanism for longevity, versus the enhancer effect or non-specific effects, remains unresolved.

Key pharmacological properties: selegiline is well absorbed orally but undergoes extensive first-pass metabolism, giving low and variable oral bioavailability (roughly 4–10%); the transdermal patch bypasses this and produces higher, more stable blood levels. The parent drug has a short half-life (around 1.5–3.5 hours), but its MAO-B inhibition is effectively irreversible, so its biological effect persists for days to weeks until new enzyme is made. It is metabolized in the liver primarily via cytochrome P450 enzymes (notably CYP2B6, with contributions from CYP2C19, CYP3A4, and others — these are enzymes that process many drugs) into L-Methamphetamine and L-Amphetamine. At oral doses at or above about 20 mg/day, MAO-B selectivity is lost and the drug also inhibits MAO-A, which is the basis for several dietary and drug interaction risks.


## Historical Context & Evolution

Selegiline was synthesized in the 1960s by Joseph Knoll and colleagues in Hungary and was initially explored as an antidepressant and a "psychic energizer." Its lasting first use emerged when it was found to be a selective MAO-B inhibitor that, unlike older non-selective MAO inhibitors, largely avoided the dangerous "cheese reaction" (a blood-pressure spike triggered by tyramine in aged foods) at low doses. It became established as an add-on to levodopa for Parkinson's disease, and a transdermal patch was later approved for major depression.

Its consideration for health optimization traces directly to Knoll's 1988 report that low-dose deprenyl more than doubled the remaining life expectancy of aged rats, alongside claims of preserved sexual and cognitive function. This caught the attention of the life-extension community, and a widely cited 1997 study reported longer survival in treated elderly dogs. These findings positioned selegiline as one of the very few compounds with repeated animal lifespan data, and it became a staple of early biohacker and longevity protocols.

The actual findings are mixed rather than uniformly positive. Several independent groups replicated a lifespan benefit in rodents, though usually smaller than Knoll's dramatic original numbers, and some strains or sexes showed little effect. In Parkinson's disease, a 1995 report from a United Kingdom research group raised alarm by suggesting higher mortality with levodopa-plus-selegiline, which damaged the drug's reputation. That signal was not confirmed: a 1998 meta-analysis of five long-term trials found no excess mortality, and the original finding is now generally attributed to study design issues rather than a true harm.

Scientific opinion has continued to evolve rather than settle. The 2025 meta-analysis strengthened the animal lifespan signal while simultaneously showing that the famous dog study lost statistical significance once age and sex were accounted for. The current standing is therefore genuinely open: the animal data are among the most robust for any candidate longevity compound, yet direct human longevity evidence does not exist, and authors on both sides agree the translatability question is unanswered.


## Expected Benefits

A dedicated search of clinical trials, systematic reviews, and expert sources was performed to compile the complete benefit profile before writing this section. Benefits are framed for risk-aware adults considering selegiline specifically for healthy aging.

### High 🟩 🟩 🟩

#### Increased Average Lifespan in Animal Models

In rodents, low-dose selegiline reproducibly extends average lifespan. A 2025 random-effects meta-analysis of 22 rodent experiments spanning 27 years, four species, and six doses found a statistically significant, moderate lifespan benefit, with no significant publication bias but substantial variability between studies; higher doses and older starting age were associated with larger effects. The proposed mechanisms are reduced oxidative stress from MAO-B inhibition and enhanced antioxidant enzyme activity. The central limitation is that this evidence is entirely animal-based and may not translate to healthy humans, and one prominent dog study lost significance on re-analysis.

**Magnitude:** Pooled standardized mean difference 0.68 (p = 0.0002) for average lifespan across 22 rodent experiments; individual studies reported average-lifespan gains ranging from roughly 10% to over 30%.

### Medium 🟩 🟩

#### Improvement of Parkinsonian Motor Symptoms

Selegiline improves motor function and can delay the need for levodopa in early Parkinson's disease, and it augments levodopa in later disease. This is its best-established human effect, supported by multiple meta-analyses of RCTs, and reflects increased dopamine availability. For a healthy-aging audience this is relevant mainly as proof that the drug measurably engages dopamine circuits in humans, not as a benefit most users would experience; effect sizes are modest and grow with treatment duration.

**Magnitude:** Mean reduction in total Unified Parkinson's Disease Rating Scale (UPDRS) score versus placebo of roughly 3–4 points at 3 months, increasing to about 8–11 points by 48–60 months in pooled trials.

#### Antidepressant Effect

Selegiline, especially as the transdermal patch, reduces depressive symptoms more than placebo, including in atypical depression. A 2023 meta-analysis of 42 studies found significant symptom reduction and higher response rates, with moderate confidence for the patch. The mechanism is increased monoamine availability (dopamine plus, at higher exposure, serotonin and noradrenaline). For longevity-oriented users, mood and motivation support is a plausible secondary benefit, though confidence in most psychiatric outcomes was rated low.

**Magnitude:** Standardized mean difference for depressive symptom reduction of about -0.96 versus placebo; response risk ratio about 1.6 overall and about 2.2 for atypical depression.

### Low 🟩

#### Neuroprotection and Preserved Cognitive/Dopaminergic Function

Selegiline may protect dopamine-producing neurons and slow age-related dopaminergic decline through antioxidant and anti-apoptotic effects, potentially preserving cognition, motivation, and coordination. Evidence is largely mechanistic and from animal models, with human cognitive data weak, inconsistent, and confounded by its use in disease populations. The benefit is biologically plausible and aligns with the longevity rationale but is not established in healthy people.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Enhanced Libido and Sexual Function

Knoll and later popular sources described deprenyl as restoring sexual activity in aged male rats and reported anecdotal libido benefits in humans, attributed partly to dopaminergic "enhancer" effects. No controlled human trials support a sexual-function benefit in healthy adults; the basis is animal data and anecdote only.

#### Immune and General "Healthspan" Effects

Some animal work reports improved immune markers and activity levels in treated older animals, fueling claims of broad healthspan benefits. These remain hypotheses extrapolated from preclinical findings, with no controlled human evidence specific to healthy aging.


## Benefit-Modifying Factors

* **Genetic polymorphisms:** Variation in CYP2B6 and CYP2C19 (liver enzymes that metabolize selegiline) alters how much active drug and how much amphetamine-type metabolite a person forms, which may shift both benefit and side-effect balance. MAO-B activity itself varies between individuals.

* **Baseline biomarker levels:** Individuals with lower baseline dopaminergic tone or higher baseline MAO-B activity (which rises with age) have, in theory, the most to gain, since the drug's effect is to restore dopamine availability.

* **Sex-based differences:** Animal lifespan studies show inconsistent results by sex, with some showing benefit predominantly in one sex; human dosing and metabolism can also differ by sex, though longevity-specific human data are absent.

* **Pre-existing health conditions:** People with early dopaminergic decline or subclinical mood symptoms may notice functional benefit, whereas healthy individuals with normal dopamine function may perceive little effect.

* **Age-related considerations:** The 2025 meta-analysis found larger lifespan effects when treatment began at older ages, suggesting benefit may be greater for adults at the older end of the target range than for younger users.


## Potential Risks & Side Effects

A dedicated search of prescribing information and drug-reference sources (FDA labeling for Eldepryl, Zelapar, and Emsam; Mayo Clinic; drugs.com) and clinical meta-analyses was performed to compile the complete risk profile before writing this section.

### High 🟥 🟥 🟥

#### Insomnia and Stimulant-Like Effects

Selegiline commonly causes insomnia, especially when dosed later in the day, because it is metabolized into L-Amphetamine and L-Methamphetamine and increases dopaminergic activity. Pooled psychiatric trial data confirm a significantly higher rate of insomnia versus placebo. It is usually manageable by morning dosing but can be persistent in sensitive individuals.

**Magnitude:** Insomnia risk ratio about 1.6 versus placebo across pooled trials.

#### Neuropsychiatric Adverse Events

Across Parkinson's disease trials, selegiline raised the overall rate of adverse events, with the excess concentrated in neuropsychiatric effects such as agitation, anxiety, confusion, hallucinations, and vivid dreams. These reflect increased dopaminergic and stimulant tone and are more likely at higher doses, in older patients, and when combined with levodopa.

**Magnitude:** Odds ratio for any adverse event about 1.58 versus placebo; neuropsychiatric adverse events about 31.6% versus 26.7%.

### Medium 🟥 🟥

#### Hypertensive Crisis at High Doses (Loss of MAO-B Selectivity)

At oral doses at or above roughly 20 mg/day, selegiline also inhibits MAO-A and loses its selectivity, restoring the risk of a dangerous blood-pressure surge (hypertensive crisis) when tyramine-rich foods (aged cheese, cured meats, some fermented products) are eaten — the classic "cheese reaction." Low longevity-style doses (around 5–10 mg/day or less) largely avoid this, but the margin shrinks as dose rises. The transdermal patch carries dietary-restriction guidance at higher strengths for the same reason.

**Magnitude:** Risk is low at ≤10 mg/day; dietary tyramine restriction is advised at oral doses ≥20 mg/day and for higher patch strengths.

#### Orthostatic Hypotension and Cardiovascular Effects

Selegiline can cause orthostatic hypotension (a drop in blood pressure on standing that causes dizziness) and other cardiovascular effects such as palpitations, particularly in older adults and when combined with other Parkinson's drugs. The mechanism involves its effects on monoamine signaling and blood-pressure regulation.

**Magnitude:** Not quantified in available studies.

### Low 🟥

#### Dry Mouth, Nausea, and Gastrointestinal Effects

Dry mouth (xerostomia) was significantly more common with selegiline than placebo in pooled psychiatric trials, and nausea, dizziness, and headache are frequently reported. These are generally mild and dose-related, reflecting the drug's monoaminergic and stimulant activity.

**Magnitude:** Dry mouth risk ratio about 1.6 versus placebo.

#### Application-Site Reactions (Transdermal)

The selegiline patch causes skin reactions at the application site more often than placebo. These are typically mild and local but can lead some users to discontinue.

**Magnitude:** Application-site reaction risk ratio about 1.8 versus placebo for the transdermal formulation.

### Speculative 🟨

#### Long-Term Risks of Amphetamine Metabolites in Healthy Users

Because selegiline yields L-Amphetamine and L-Methamphetamine, there is theoretical concern about cumulative stimulant exposure, dependence potential, or cardiovascular strain with indefinite use in otherwise healthy people. No controlled long-term data in healthy longevity users exist; the concern is mechanistic and extrapolated from amphetamine pharmacology.

#### Historically Alleged Increased Mortality

An early Parkinson's report suggested higher mortality with selegiline plus levodopa, but a subsequent meta-analysis found no excess mortality, and the signal is now attributed to study design. It is listed here as a resolved-but-not-forgotten concern rather than an established risk.


## Risk-Modifying Factors

* **Genetic polymorphisms:** Poor or rapid metabolizers at CYP2B6 and CYP2C19 (enzymes that process selegiline) may generate more amphetamine-type metabolites, potentially increasing insomnia, agitation, and cardiovascular side effects.

* **Baseline biomarker levels:** Pre-existing low blood pressure raises the chance of symptomatic orthostatic hypotension, and elevated baseline blood pressure increases concern about the tyramine reaction at higher doses.

* **Sex-based differences:** Side-effect frequency can differ by sex partly through differences in body size and metabolism; dedicated comparative data in healthy users are lacking.

* **Pre-existing health conditions:** People with psychiatric illness (especially bipolar disorder or psychosis), cardiovascular disease, or a history of substance use disorder face higher risk from the drug's stimulant and dopaminergic effects.

* **Age-related considerations:** Older adults — including those at the upper end of the target range — are more prone to neuropsychiatric effects, confusion, and orthostatic hypotension, so risk rises with age even as the animal lifespan benefit appears to rise with age.


## Key Interactions & Contraindications

* **Antidepressants (serotonergic):** Combining selegiline with selective serotonin reuptake inhibitors (SSRIs, such as fluoxetine, sertraline), serotonin-noradrenaline reuptake inhibitors (SNRIs, such as venlafaxine, duloxetine), or tricyclic antidepressants risks serotonin syndrome (a dangerous excess of serotonin causing agitation, fever, rapid heart rate). Severity: absolute contraindication; a washout period (e.g., several weeks, and up to 5 weeks after fluoxetine) is required.

* **Other monoamine oxidase inhibitors:** Co-use with other MAO inhibitors can cause hypertensive crisis or serotonin syndrome. Severity: absolute contraindication.

* **Opioids:** Meperidine (pethidine) and related opioids (tramadol, methadone, dextromethorphan in cough products) can cause severe, sometimes fatal reactions. Severity: absolute contraindication for meperidine; caution and avoidance for others.

* **Sympathomimetics and stimulants:** Decongestants (pseudoephedrine, phenylephrine), amphetamines, and other stimulants can compound blood-pressure and cardiovascular effects. Severity: caution to contraindication; avoid concurrent use.

* **Over-the-counter medications:** OTC cold and allergy products containing dextromethorphan or sympathomimetic decongestants (pseudoephedrine, phenylephrine) should be avoided. Severity: caution; choose products without these ingredients.

* **Supplement interactions:** Supplements that raise serotonin or catecholamines — 5-HTP, L-Tryptophan, St. John's wort, high-dose L-Tyrosine or L-Phenylalanine, and yohimbine — may add to serotonergic or pressor effects. Severity: caution; separate use or avoid.

* **Additive dopaminergic/stimulant supplements:** Supplements that also increase dopamine or stimulate the nervous system (e.g., Mucuna pruriens, which contains L-Dopa; high-dose caffeine) can amplify selegiline's stimulant and dopaminergic effects, increasing insomnia and agitation. Severity: caution; monitor and consider timing separation.

* **Other intervention interactions:** With levodopa, selegiline potentiates dopaminergic effects and can worsen dyskinesias and neuropsychiatric symptoms; dose adjustment of levodopa may be needed. Severity: caution; monitor.

* **Dietary tyramine:** At higher doses, tyramine-rich foods can trigger hypertensive crisis (see Risks). Severity: caution at ≤10 mg/day, dietary restriction at ≥20 mg/day oral or higher patch strengths; the mitigating action is dose limitation and food avoidance.

* **Populations who should avoid it:** People taking any contraindicated serotonergic drug or other MAO inhibitor; those with pheochromocytoma; individuals with uncontrolled hypertension; people with active psychosis or poorly controlled bipolar disorder; those scheduled for surgery requiring general anesthesia or certain opioids; and pregnant or breastfeeding individuals, given the amphetamine metabolites and absence of safety data.


## Risk Mitigation Strategies

* **Keep the dose low to preserve MAO-B selectivity:** Longevity-oriented use typically stays at or below 5–10 mg/day orally (or low-strength patches), which keeps MAO-A largely uninhibited and minimizes the tyramine hypertensive-crisis risk that appears at ≥20 mg/day.

* **Dose in the morning to reduce insomnia:** Because selegiline forms stimulant metabolites, taking it on waking (and avoiding afternoon or evening dosing) mitigates the high-frequency insomnia and sleep disruption seen in trials.

* **Observe drug washout windows:** To prevent serotonin syndrome and hypertensive reactions, stop interacting antidepressants well before starting selegiline (commonly 2 weeks, and 5 weeks after fluoxetine), directly preventing the most dangerous interaction-related events.

* **Screen and avoid contraindicated medications and supplements:** Reviewing all prescriptions, OTC cold/allergy products, and supplements for serotonergic, sympathomimetic, or opioid agents before starting prevents the severe interaction reactions listed above.

* **Limit tyramine intake if using higher doses:** If a dose at or above 20 mg/day (or a higher patch strength) is used, avoiding aged cheeses, cured meats, and fermented products mitigates the risk of hypertensive crisis.

* **Monitor blood pressure and mood:** Checking blood pressure (including on standing) and watching for agitation, anxiety, or confusion allows early detection of orthostatic hypotension and neuropsychiatric adverse events, the side effects most elevated in trials.


## Therapeutic Protocol

* **Standard low-dose longevity approach:** Among longevity practitioners, the most commonly described protocol uses low intermittent oral dosing — often on the order of 1–5 mg per day, or a few milligrams a few times per week, rather than the 5–10 mg/day used for Parkinson's disease. The rationale, articulated by Knoll and adopted in life-extension circles, is to gain the proposed enhancer and antioxidant effects while staying well below the threshold for MAO-A inhibition.

* **Conventional disease dosing for comparison:** The established Parkinson's regimen is 5–10 mg/day (often 5 mg at breakfast and 5 mg at lunch for the oral tablet, or once-daily orally disintegrating tablets at lower equivalent doses); the depression patch (Emsam) is dosed at 6–12 mg/24 hours. These are presented as reference points, not as longevity protocols.

* **Competing approaches:** A conventional, evidence-first position holds that, absent human longevity data, there is no validated healthy-aging protocol and selegiline should be reserved for its approved indications. An integrative/longevity position favors cautious low-dose off-label use based on the animal data. Neither is framed here as the default.

* **Best time of day:** Morning dosing is generally described to align the drug's stimulant metabolites with the daytime and to minimize insomnia.

* **Half-life:** The parent drug's plasma half-life is short (about 1.5–3.5 hours), but because MAO-B inhibition is irreversible, the functional effect persists for days to weeks; this is why infrequent dosing is plausible.

* **Single vs. split dosing:** For disease doses, splitting between breakfast and lunch is conventional; for low longevity doses, once-daily or intermittent (every-other-day or few-times-weekly) dosing is commonly described, taking advantage of the irreversible enzyme inhibition.

* **Genetic polymorphisms:** Variants in CYP2B6 and CYP2C19 (drug-metabolizing enzymes) may influence active-drug and metabolite levels and thus the dose a person tolerates; pharmacogenetic testing is not standard but may rationalize starting low.

* **Sex-based differences:** Animal lifespan responses differ by sex and human metabolism varies with body size; lower starting doses are reasonable for smaller individuals.

* **Age-related considerations:** Older adults are more sensitive to neuropsychiatric and blood-pressure effects, so starting at the low end and titrating slowly is described, even though the animal benefit appears larger with older starting age.

* **Baseline biomarker levels:** Baseline blood pressure (including standing) and mood/sleep status inform starting dose and monitoring intensity.

* **Pre-existing health conditions:** Psychiatric, cardiovascular, and substance-use history shape whether and how cautiously the drug is introduced.


## Discontinuation & Cycling

* **Lifelong vs. short-term:** For longevity purposes the intended duration is undefined; animal protocols often ran for the remainder of life, but no human data establish an optimal duration, so use is open-ended and experimental.

* **Withdrawal effects:** Abrupt discontinuation of MAO inhibitors can occasionally cause a discontinuation syndrome (agitation, confusion, or rebound symptoms), more relevant at higher antidepressant-range doses than at low longevity doses.

* **Tapering:** A gradual dose reduction is generally advised when stopping after sustained use, particularly from higher doses, to avoid discontinuation effects; the irreversible enzyme inhibition also means full MAO-B activity returns only over days to weeks as new enzyme is synthesized.

* **Cycling:** Because MAO-B inhibition is irreversible and long-lasting, some longevity users deliberately use intermittent or cyclical dosing (e.g., a few days per week) both to limit cumulative stimulant-metabolite exposure and because daily dosing is not required to maintain enzyme inhibition; whether cycling preserves efficacy is unproven.

* **Practical framing:** Each of the above considerations is hypothesis-driven for the healthy-aging use case, since the discontinuation and cycling literature derives from disease populations.


## Sourcing and Quality

* **Prescription status:** Selegiline is a prescription medication, so the primary quality safeguard is obtaining it through a licensed pharmacy dispensing an approved product (Eldepryl, Zelapar orally disintegrating tablets, or the Emsam patch) rather than from unregulated online vendors.

* **Formulation choice:** Oral tablets/capsules, orally disintegrating tablets (which bypass some first-pass metabolism), and the transdermal patch differ markedly in bioavailability and blood-level stability; the formulation affects both dosing precision and interaction risk.

* **Compounding pharmacies:** Because approved tablets come in 5 mg strengths that exceed typical low longevity doses, some users obtain lower-dose (e.g., 1 mg) capsules from reputable compounding pharmacies; verifying the pharmacy's licensing and quality controls is important.

* **Avoiding gray-market products:** Liquid "deprenyl" and unbranded products sold for longevity online carry risks of inaccurate dosing, contamination, or misidentification; third-party-tested or pharmacy-dispensed sources should be preferred.


## Practical Considerations

* **Time to effect:** Subjective effects on alertness or mood may appear within days to a few weeks; any putative longevity or neuroprotective benefit, by definition, cannot be perceived by the individual and is inferred only from animal data.

* **Common pitfalls:** Dosing too high (crossing into MAO-A inhibition and tyramine risk), dosing too late in the day (insomnia), failing to observe antidepressant washout windows, and combining with contraindicated cold remedies or supplements are the most frequent mistakes.

* **Regulatory status:** Selegiline is FDA-approved only for Parkinson's disease (oral) and major depression (transdermal). All longevity use is off-label, and it is not approved or marketed as an anti-aging agent.

* **Cost and accessibility:** Generic oral selegiline is inexpensive and widely available by prescription; the branded patch and compounded low-dose capsules are more costly, but cost is not a major barrier overall.


## Interaction with Foundational Habits

* **Sleep:** Direct and blunting. Selegiline's stimulant metabolites (L-Amphetamine, L-Methamphetamine) frequently disrupt sleep and cause insomnia, as shown in pooled trials. The practical mitigation is strict morning-only dosing and avoiding caffeine late in the day.

* **Nutrition:** Direct and potentially hazardous at higher doses. At ≥20 mg/day oral (or higher patch strengths) the drug interacts with dietary tyramine (aged cheese, cured meats, fermented foods) to raise blood pressure; at low longevity doses this interaction is minimal, but awareness of tyramine-rich foods remains prudent.

* **Exercise:** Indirect and generally neutral to mildly potentiating. By raising dopamine and providing mild stimulation, selegiline may modestly increase drive for activity; there is no evidence it blunts training adaptations, but combining it with stimulant pre-workouts could amplify cardiovascular and blood-pressure effects, so timing separation is sensible.

* **Stress management:** Indirect. Through dopaminergic and mild stimulant effects, selegiline can increase arousal and, in sensitive individuals, anxiety or agitation; pairing it with stress-reduction practices and avoiding additional stimulants helps keep the stress response balanced.


## Monitoring Protocol & Defining Success

Before starting, a baseline assessment is appropriate to establish blood pressure (seated and standing), mood and sleep status, and a review of all medications and supplements for interactions. Ongoing monitoring should begin within the first weeks and continue periodically — for example, at about 1–2 weeks and 4–6 weeks after starting or dose changes, then every 6–12 months thereafter.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| Blood pressure (seated & standing) | ~110–125 / 70–80 mmHg; <20 mmHg systolic drop on standing | Detects orthostatic hypotension and any pressor response | Measure both positions; check more often after dose increases; standing measurement catches orthostatic drops |
| Resting heart rate | ~50–70 bpm | Flags stimulant-related cardiovascular effects | Best measured at rest, same time of day |
| Mood & anxiety screen (e.g., standardized questionnaire) | Stable, no worsening | Detects neuropsychiatric adverse events (agitation, anxiety) | Qualitative tracking complements; review at each follow-up |
| Sleep quality (objective or self-tracked) | ≥7 hours, good continuity | Insomnia is the most common side effect | A wearable or sleep diary helps; deterioration suggests dosing too late or too high |
| Liver enzymes (ALT, AST) | ALT/AST ~10–30 U/L (functional); conventional upper limit ~40 U/L | Drug is hepatically metabolized; baseline and periodic check is prudent | Functional ranges are tighter than conventional lab cutoffs; fasting not strictly required |

Qualitative markers are an important part of judging success and tolerability:

* Energy and motivation levels
* Mood and sense of wellbeing
* Cognitive clarity and focus
* Sleep quality and ease of falling asleep
* Any agitation, anxiety, palpitations, or dizziness on standing


## Emerging Research

* **Skin-irritation and sensitization study of a selegiline transdermal system:** A Phase 1 study assessing irritation and sensitization of a selegiline patch in healthy subjects, enrolling about 230 participants, with primary endpoints of skin irritation and sensitization. [NCT07452692](https://clinicaltrials.gov/study/NCT07452692).

* **Bioavailability and adhesion study of a selegiline transdermal system:** A Phase 1 study in about 92 healthy adults evaluating bioequivalence of a test selegiline patch versus the Emsam patch and assessing patch adhesion. [NCT07571824](https://clinicaltrials.gov/study/NCT07571824).

* **Translational longevity question:** The 2025 rodent lifespan meta-analysis ([Bene, 2025](https://pubmed.ncbi.nlm.nih.gov/40816452/)) explicitly calls for clinical studies of L-Deprenyl's effects on health outcomes in older adults; such trials, if conducted, could strengthen the case for human longevity benefit — or, like the re-analyzed dog study, weaken it.

* **Comparative MAO-B inhibitor research:** Network meta-analyses comparing selegiline with newer MAO-B inhibitors ([Wang & Wang, 2024](https://pubmed.ncbi.nlm.nih.gov/39278214/)) suggest agents such as rasagiline may be more effective for motor symptoms; future head-to-head work could clarify whether any MAO-B inhibitor offers a distinct healthy-aging advantage or whether selegiline's animal lifespan signal is compound-specific.

* **Enhancer-effect mechanism:** Knoll's proposed catecholaminergic-activity-enhancer mechanism, distinct from MAO-B inhibition, remains an open research area; confirming or refuting it in humans would directly affect whether very low doses have any longevity-relevant action.


## Conclusion

Selegiline is a long-established prescription medicine, used for Parkinson's disease and depression, that has drawn longevity interest because it blocks a brain enzyme whose activity rises with age and because low doses have repeatedly extended the average lifespan of rats and other animals. Pooled animal data point to a consistent average lifespan benefit, making it one of the better-supported candidate longevity compounds in animals — yet a famous dog study did not hold up on closer inspection, and there is no direct evidence that any of this applies to healthy people.

Its human track record is in treating disease, not extending life: it modestly improves Parkinsonian movement and lifts mood, while commonly causing trouble sleeping and, at higher doses, carrying serious interaction and blood-pressure risks. Its breakdown into amphetamine-like substances raises unanswered questions about long-term use in healthy individuals.

The honest summary is that the animal data are genuinely intriguing and the mechanism is plausible, but the gap between animal lifespan findings and proven human benefit is wide and untested. Anyone weighing it for healthy aging is acting on early, indirect evidence, with real and well-documented side effects on the other side of the ledger.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**